Syncona (SYNC) Q3 2026 TU earnings summary

Executive summary

• Achieved positive NAV performance with a 3.6% NAV per share return for the quarter ended 31 December 2025, driven by Beacon's valuation uplift and Autolus' share price appreciation.

• Portfolio is well-positioned for multiple key value inflection points, with improving biotech market conditions supporting future growth.

Financial highlights

• Net assets increased to £1,058.2 million (173.9p per share) from £1,020.9 million (167.9p per share) as of 30 September 2025.

• Life Science Portfolio valued at £840.1 million, up from £750.2 million, delivering a 5.0% return in the quarter.

• Over nine months, NAV per share returned 1.8% and the Life Science Portfolio generated a 3.3% return.

• Capital pool stood at £218.1 million at 31 December 2025, with £52.6 million deployed in the quarter.

Outlook and guidance

• Eight key value inflection points expected over the next three years, with four anticipated in calendar year 2026 from commercial and late-stage clinical companies.

• Portfolio is funded to deliver on these milestones, with potential for significant NAV growth through M&A and liquidity events.

• Quell's key milestone delayed to 2027 due to strategic reprioritization, focusing on a larger commercial opportunity.